Felix S. Lichtenegger

Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML

Sascha Haubner, Fabiana Perna, Thomas Köhnke et al. · Leukemia · 2018 · 328 citations · Full text

Medicine, Hematology, Oncology +17

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Christina Krupka, Peter Kufer, Roman Kischel et al. · Blood · 2013 · 207 citations

Life Sciences, Immunology, Molecular Biology +17

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells

Felix S. Lichtenegger, Maurine Rothe, Frauke M. Schnorfeil et al. · Frontiers in Immunology · 2018 · 184 citations · Full text

Life Sciences, Immunology, Oncology +17

T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment

Frauke M. Schnorfeil, Felix S. Lichtenegger, Katharina Emmerig et al. · Journal of Hematology & Oncology · 2015 · 145 citations · Full text

Life Sciences, Hematology, Immunology +17

Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours

Ignacio Melero, Maria de Miguel Luken, Guillermo de Velasco et al. · Nature · 2024 · 93 citations · Full text

Life Sciences, Immunology, Oncology +17